US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Galecto, Inc.

News headline image
Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022
From Galecto, Inc.
Via GlobeNewswire
Tickers GLTO
News headline image
Galecto to Participate in Oppenheimer’s 33rd Annual Healthcare Conference
From Galecto, Inc.
Via GlobeNewswire
Tickers GLTO
News headline image
Galecto to Participate in SVB Securities Global Biopharma Conference
From Galecto, Inc.
Via GlobeNewswire
Tickers GLTO
News headline image
Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting
From Galecto, Inc.
Via GlobeNewswire
Tickers GLTO
News headline image
Galecto Reports Third Quarter Operating and Financial Results
From Galecto, Inc.
Via GlobeNewswire
Tickers GLTO
News headline image
Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients
From Galecto, Inc.
Via GlobeNewswire
Tickers GLTO
News headline image
Galecto to Participate in Jefferies London Healthcare Conference
From Galecto, Inc.
Via GlobeNewswire
Tickers GLTO
News headline image
Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD’s The Liver Meeting® 2022
From Galecto, Inc.
Via GlobeNewswire
Tickers GLTO
News headline image
Galecto’s Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute
From Galecto, Inc.
Via GlobeNewswire
Tickers GLTO